

***Amendments to the Claims:***

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

40. (Currently Amended) A method for diagnosing breast cancer in a subject, comprising:

determining a level levels of expression of a p14 peptide in one or more fluid samples from the said subject,

wherein when the a-high level of expression is above a determined standard, there is signifying a high probability for breast cancer in the said subject.

41. (Currently Amended) The method of claim Claim 40, further comprising assaying for the level of p14 peptide in [[a]] the fluid sample obtained from the subject, the assaying comprising said method comprises:

[[a)]] contacting the fluid said sample with anti-p14 antibodies,[[;]]

[[b)]] determining binding of the anti-p14 antibodies to the p14 peptide.

42. (Currently Amended) The method of claim Claim 41, wherein the fluid said sample is a tissue or body fluid sample excised or withdrawn from a breast lump or other suspicious area in the breast of the subject.

43. (Currently Amended) The method of ~~claim~~ Claim 42, wherein said the fluid sample is selected from the group consisting of whole blood, blood serum, milk and saliva ~~from fresh biopsy section, cryo section or paraffin embedded section.~~

44. (Currently Amended) The method of claim Claim 40, wherein said the fluid sample is ~~[[a]]~~ blood serum ~~sample.~~

45. (Withdrawn) The method of Claim 40, comprising assaying for the level of anti-p14 antibodies in a sample obtained from the subject, said method comprises: (a) contacting said sample with p14 peptide;(b) determining binding of p14 peptide to anti-p14 antibodies.

46. (Withdrawn) The method of Claim 45, wherein said p14 peptide is His-tag p14 peptide comprising the sequence depicted in SEQ ID NO:2.

47. (Currently Amended) A method for screening fluid samples ~~from subjects~~ into such which ~~signify that subjects from which they were obtained have a relatively high possibility of having or being susceptible of developing breast cancer and such which signify that subjects from which they were obtained have a relatively lower probability of having or being susceptible of developing breast cancer~~, the method comprising: contacting each of the fluid samples from the subjects with anti-p14 antibodies and determining binding of anti-p14 antibodies and p14 peptide, if present in said the sample,

wherein when a high degree of binding is higher than a determined standard there is signifying a corresponding higher probability [[of]] that the subject from which the sample was obtained has developed, having or is being susceptible to [[of]] developing, breast cancer.

48. (Currently Amended) The method of claim Claim 47, wherein said the fluid sample is a ~~tissue or body~~ fluid sample excised or withdrawn from an ~~suspicious~~ area in a the breast of the subject.

49. (Currently Amended) The method of claim Claim ~~[[48]]~~47, wherein said the fluid sample is selected from ~~fresh biopsy section, cryo-section or paraffin-embedded section~~ the group consisting of whole blood, blood serum, milk and saliva.

50. (Currently Amended) The method of claim Claim ~~[[49]]~~48, wherein said the sample is a blood serum sample.

51. (Withdrawn) A method for screening samples into such which signify that subjects from which they were obtained have a relatively high possibility of having or being susceptible of developing breast cancer and such which signify that subjects from which they were obtained have a relatively lower probability of having or being susceptible of developing breast cancer, the method comprising contacting the samples with p14 peptide and determining binding of p14 peptide with anti-p14 antibodies, a high degree of binding signifying a corresponding higher probability of having or being susceptible of developing breast cancer.

52. (Withdrawn) The method of Claim 51, wherein said sample is a blood sample.

53. (Withdrawn) The method of Claim 52, wherein said p14 peptide is His-tag p14 peptide comprising the sequence depicted in SEQ ID NO:2.

54. (Withdrawn) A method for the treatment of breast cancer comprising administering to a subject in need of anti-breast cancer treatment an amount of anti-p14 antibodies, the amount being sufficient to achieve an anti cancer effect in said subject.

55. (Withdrawn) The method of Claim 54, wherein said anti-p14 antibodies are humanized antibodies.

56. (Withdrawn) The method of Claim 54, wherein said anti-p14 antibodies are bound to a protein transducing element.

57. (Withdrawn) The method of Claim 56, wherein said protein transducing element is the (37-72) Tat fragment of HIV-HV1B1 Tat.

58. (Withdrawn) The method of Claim 54, wherein said anti-p14 antibodies are bound to a cytotoxic agent.

59. (Withdrawn) A method for the treatment of breast cancer comprising administering to a subject in need an amount of p14 peptide, the amount being effective to elicit production of anti-p14 antibodies in said subject.

60. (Withdrawn) pharmaceutical composition for the treatment of breast cancer comprising as active ingredient an amount of anti-p14 antibodies, the amount being sufficient to achieve a therapeutic effect in said subject.

61. (Withdrawn) The pharmaceutical composition of Claim 60, wherein said anti-p14 antibodies are humanized antibodies.

62. (Withdrawn) The pharmaceutical composition of Claim 61, wherein said anti-p14 antibodies are bound to a protein transducing element.

63. (Withdrawn) The pharmaceutical composition of Claim 62, wherein said protein transducing element is the (37-72) Tat fragment of HIV-HV1B1 Tat.

64. (Withdrawn) The pharmaceutical composition of Claim 60, wherein said anti-p14 antibodies are bound to a cytotoxic agent.

65. (Withdrawn) A vaccine comprising as active ingredient an amount of p14 peptide or an immunogenic fragment thereof, the amount being sufficient to elicit in a subject production of anti-p14 antibodies.